These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9228671)

  • 1. Expression of CD44V2 in transitional cell carcinoma of the urinary bladder and in urine.
    Müller M; Heicappell R; Habermann F; Kaufmann M; Steiner U; Miller K
    Urol Res; 1997; 25(3):187-92. PubMed ID: 9228671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
    McKenney JK; Desai S; Cohen C; Amin MB
    Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panel.
    Irwin T; Donlan AW; Owens L; Alvarez R; Vakar-Lopez F; Tretiakova M
    Hum Pathol; 2024 Apr; 146():43-48. PubMed ID: 38593961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.
    Aron M; Luthringer DJ; McKenney JK; Hansel DE; Westfall DE; Parakh R; Mohanty SK; Balzer B; Amin MB
    Am J Surg Pathol; 2013 Dec; 37(12):1815-23. PubMed ID: 24225842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive loss of CD44 gene expression in invasive bladder cancer.
    Sugino T; Gorham H; Yoshida K; Bolodeoku J; Nargund V; Cranston D; Goodison S; Tarin D
    Am J Pathol; 1996 Sep; 149(3):873-82. PubMed ID: 8780391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197.
    Kuncová J; Kostrouch Z; Viale M; Revoltella R; Mandys V
    Folia Biol (Praha); 2005; 51(1):3-11. PubMed ID: 15783086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma?
    Buchumensky V; Klein A; Zemer R; Kessler OJ; Zimlichman S; Nissenkorn I
    J Urol; 1998 Dec; 160(6 Pt 1):1971-4. PubMed ID: 9817302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.
    Gomella LG; Mann MJ; Cleary RC; Hubosky SG; Bagley DH; Thumar AB; McCue PA; Lallas CD; Trabulsi EJ
    Can J Urol; 2017 Feb; 24(1):8620-8626. PubMed ID: 28263126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma.
    Ross JS; del Rosario AD; Bui HX; Kallakury BV; Okby NT; Figge J
    Mod Pathol; 1996 Aug; 9(8):854-60. PubMed ID: 8871928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.
    Oliva E; Pinheiro NF; Heney NM; Kaufman DS; Shipley WU; Gurski C; Spicer B; Paner GP; Gown AM; Amin MB
    Hum Pathol; 2013 May; 44(5):860-6. PubMed ID: 23199526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns.
    Miyake H; Hara I; Kamidono S; Eto H
    J Urol; 2004 Sep; 172(3):1127-9. PubMed ID: 15311055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine.
    Chopin DK; Caruelle JP; Colombel M; Palcy S; Ravery V; Caruelle D; Abbou CC; Barritault D
    J Urol; 1993 Oct; 150(4):1126-30. PubMed ID: 7690426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
    Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
    APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voided urine versus bladder washing cytology for detection of urothelial carcinoma: which is better?
    Keller AK; Jensen JB
    Scand J Urol; 2017 Aug; 51(4):290-292. PubMed ID: 28398114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD44s and CD44v6 in diagnosis and prognosis of human bladder cancer.
    Omran OM; Ata HS
    Ultrastruct Pathol; 2012 May; 36(3):145-52. PubMed ID: 22559040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
    Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
    Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Urinary cytology. Possibilities, limitations and the future].
    Zaak D; Tritschler S; Knuechel R; Vom Dorp F; Hakenberg OW; Hautmann S; Rübben H
    Urologe A; 2006 Sep; 45 Suppl 4():97-101. PubMed ID: 16821054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LASP-1, a novel urinary marker for detection of bladder cancer.
    Ardelt P; Grünemay N; Strehl A; Jilg C; Miernik A; Kneitz B; Butt E
    Urol Oncol; 2013 Nov; 31(8):1591-8. PubMed ID: 22481019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of CD44 variant 6 expression differentiates small cell carcinoma of urinary bladder from urothelial (transitional cell) carcinoma.
    Iczkowski KA; Shanks JH; Bostwick DG
    Histopathology; 1998 Apr; 32(4):322-7. PubMed ID: 9602328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.